Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Poly(ADP-ribose) polymerase family proteins (PARPs) are a group of enzymes that catalyze ADP-ribosylation of target proteins using NAD+ as a substrate, with central roles in DNA repair, chromatin remodeling, and the regulation of cell death. There are at least 17 PARP family members in humans, of which PARP1, PARP2, and tankyrases are the best-characterized. PARPs respond to DNA damage by attaching long, branched chains of poly(ADP-ribose) (PAR) to themselves and other nuclear proteins, facilitating recruitment of DNA repair machinery, and modulating transcription, cell fate decisions, and genome maintenance. PARP inhibition is a clinically validated strategy for cancer therapy, especially for tumors deficient in homologous recombination repair (e.g., BRCA mutant cancers).
Inhibition of ADP-ribosylation enzymatic activity\nBlockage of DNA repair pathway, leading to synthetic lethality (especially in cells with BRCA1/2 mutations)\nSensitization of tumor cells to DNA-damaging agents
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Poly(ADP-ribose) polymerase family (PARP family).